Skip to main content
. 2021 Feb 20;41:101907. doi: 10.1016/j.redox.2021.101907

Table 3.

Mass-specific respiration rates in the critically ill and reference cohorts.

JO2 per mass (pmol/s/mg wet weight) median (IQR) Reference group (n = 9) Critically ill patients < 48 h (n = 21) Critically ill patients day 5–7 (n = 12)
LEAKFAO 5.49 (4.82–6.75) 4.55 (3.17–5.51) * 4.54 (3.62–6.02)
OXPHOSFAO 14.7 (10.5–17.1) 9.96 (7.16–10.8) ** 9.25 (7.20–13.4) *
OXPHOSCI 26.2 (19.6–31.3) 20.5 (17.3–23.5) 26.8 (22.0–30.8)##
OXPHOSMAX 44.6 (38.4–59.4) 44.8 (38.0–53.2) 47.5 (45.9–58.2)
ETSMAX 53.0 (45.8–71.8) 55.59 (48.0–66.6) 62.6 (57.5–71.5)##
ETSCII 24.3 (21.0–32.9) 24.5 (22.5–27.8) 25.5 (22.2–32.3)

Respiratory capacities generated by sequential addition of substrates, uncouplers and inhibitors according to previously described SUIT protocol. JO2: oxygen consumption rate at steady state; LEAKFAO: capacity for respiration supported by proton leak, in the presence of malate and octanoyl carnitine and absence of ADP; OXPHOSFAO: capacity for oxidative phosphorylation supported by FAO, following addition of saturating ADP; OXPHOSCI: capacity for oxidative phosphorylation supported by complex I; following addition of saturating pyruvate and glutamate; OXPHOSMAX: maximum capacity for oxidative phosphorylation supported by complex I and complex II, following addition of succinate; ETSMAX: maximum capacity of the electron transport system uncoupled from oxidative phosphorylation, following titration of uncoupler; ETSCII; capacity of uncoupled electron transport system supported by complex II alone, following inhibition of complex I by rotenone. *p < 0.05, **p < 0.01 vs reference group; #p < 0.05, ##p < 0.01 vs critically ill patients within 48 h.